Gosuranemab  (Synonyms: BMS-986168; IPN007; BIIB092)

Gosuranemab (BMS-986168; IPN007; BIIB092) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

Tau

Gosuranemab exhibits high binding affinity to monomeric and aggregated tau and removes seeding-competent tau from AD brain lysate^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Gosuranemab (murine version IPN002; weekly; 8 weeks) reduces unbound tau levels in the cerebrospinal fluid and interstitial fluid of rTg4510 tauopathy transgenic mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

4137  [NCBI]

P10636

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.94 kDa

1788032-39-2

Liquid

Colorless to light yellow

[Gosuranemab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized Fetal-tau/0N3R Protein, Human (His, solution, HY-P73618) can bind Gosuranemab. The EC₅₀ for this effect is 3.367 ng/mL.
• 
  Flow cytometric analysis of 1.5X10⁶ SHSY5Y cells with Gosuranemab (HY-P99648, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa, Isotype Control (HY-P99003, blue) was used as the isotype control.

• [1]. Dam T, et al. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021;27(8):1451-1457.

  [2]. Shulman M, et al. TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease. Nat Aging. 2023;3(12):1591-1601.